L. J. van ‘t Veer

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

5.3Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Papers

Driven by 41 papers — median percentile 72. Top paper: “Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies”.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types

Nature Communications(2019)10.1038/s41467-019-11415-2

N/A

4.4DataRank · unranked

165 citations

BIN CHEN, Dvir Aran, J. Charalel, L. J. van ‘t Veer, Atul Janardhan Butte +6 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.502

N/A

0.832DataRank · unranked

16 citations

Hanna Bandos, Peter C. Lucas, L. J. van ‘t Veer, Jia-Perng Jennifer Wei, Charles E. Geyer +15 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0.777DataRank · unranked

177 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk

npj Breast Cancer(2021)10.1038/s41523-021-00239-3

N/A

0.598DataRank · unranked

53 citations

Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart +12 more

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

Nature Cancer(2023)10.1038/s43018-022-00508-5

N/A

0.574DataRank · unranked

45 citations

Chloé E. Atreya, Changjun Wang, Bo Pan, Courtney A. Dreyer, Diede Brunen +20 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312

N/A

0.442DataRank · unranked

18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06914-2

N/A

0.441DataRank · unranked

7 citations

Rebecca Shatsky, Richard B. Schwab, Anne M. Wallace, Denise M. Wolf, Gillian L. Hirst +7 more

Development and testing of a polygenic risk score for breast cancer aggressiveness

npj Precision Oncology(2023)10.1038/s41698-023-00382-z

N/A

0.373DataRank · unranked

11 citations

Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart +18 more

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

JAMIA Open(2021)10.1093/jamiaopen/ooab038

Top 51%

0.346DataRank

Top 51%2 citations

David L. Gibbs, Kawther Abdilleh, Adam L. Asare, Smita Asare, Sara J. Venters +8 more

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Nature Communications(2025)10.1038/s41467-025-65432-5

N/A

0.292DataRank · unranked

6 citations

Nayelis A. Manon, Denise M. Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Rosalyn W. Sayaman +20 more

Development and testing of a polygenic risk score for breast cancer aggressiveness

medRxiv(2022)10.1101/2022.08.26.22278957

N/A

0.165DataRank · unranked

2 citations

Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart +18 more

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

Journal of Clinical Oncology(2023)10.1200/jco.22.01978

N/A

0DataRank · unranked

28 citations

Irene L. Andrulis, Stig E. Bojesen, Thilo Dörk, Diana Eccles, Peter A. Fasching +95 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

Frontiers in Oncology(2023)10.3389/fonc.2023.1192208

N/A

0DataRank · unranked

5 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +10 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.30.534178

N/A

0DataRank · unranked

0 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +11 more

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2928

N/A

0DataRank · unranked

13 citations

Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau +13 more

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae268

N/A

0DataRank · unranked

5 citations

Huma Dar, Anna Nordenskjöld, Gizeh Pérez‐Tenorio, Nicholas P. Tobin, Christina Yau +8 more

Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.03.19.585748

N/A

0DataRank · unranked

6 citations

Jung Min Suh, Brian J Woo, Albertas Navickas, Kristle Garcia, Keyi Yin +11 more

Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.10600

N/A

0DataRank · unranked

0 citations

Pooja Middha, Zoe Quandt, Yiwey Shieh, Amrita Basu, Rosalyn W. Sayaman +11 more

MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer

Tomography(2025)10.3390/tomography11030026

N/A

0DataRank · unranked

4 citations

Natsuko Onishi, Jessica Gibbs, Lisa J. Wilmes, Nu N. Le, Pouya Metanat +12 more

Super-enhancer profiling reveals ThPOK/ZBTB7B, a CD4+ cell lineage commitment factor, as a master regulator that restricts breast cancer cells to a luminal non-migratory phenotype

Cellular and Molecular Life Sciences(2025)10.1007/s00018-025-05913-4

N/A

0DataRank · unranked

1 citations

Kamin Kahrizi, Rosalyn W. Sayaman, Carolina DiBenedetto, Pedro J Salaberry, Roxana Pirker +14 more

Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer

Research Square(2025)10.21203/rs.3.rs-6926989/v1

N/A

0DataRank · unranked

2 citations

Xiaopeng Sun, Ann Hanna, Andres A. Ocampo, Brandie C. Taylor, James R. Marshall +14 more

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial

Frontiers in Oncology(2025)10.3389/fonc.2025.1605120

N/A

0DataRank · unranked

0 citations

Justin Lengfeld, S.P. Stoesz, Michelle Edwards, Franklin Pass, Gillian L. Hirst +6 more

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

Annals of Oncology(2020)10.1016/j.annonc.2020.11.007

N/A

0DataRank · unranked

445 citations

Lamorna Brown Swigart, H.-T. Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +19 more

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.506

N/A

0DataRank · unranked

65 citations

L. J. van ‘t Veer, Coralie Poncet, Josephine Lopes Cardozo, Suzette Delaloge, Jean‐Yves Pierga +15 more

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival

medRxiv(2020)10.1101/2020.02.03.20019760

N/A

0DataRank · unranked

41 citations

Lamorna Brown Swigart, Hsin-Ta Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +18 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0DataRank · unranked

73 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study

npj Breast Cancer(2021)10.1038/s41523-021-00366-x

N/A

0DataRank · unranked

24 citations

Amy M. Shui, Michelle Melisko, A. Jo Chien, Emi Yoshida, Elizabeth Lancaster +4 more

Combinatorial Immunotherapies Overcome MYC-Driven Immune Evasion

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.05.07.442684

N/A

0DataRank · unranked

4 citations

Filomena Housley, Christina Yau, Daniel Van de Mark, Rachel Nakagawa, Golzar Hemmati +11 more

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Nature Communications(2022)10.1038/s41467-022-31238-y

N/A

0DataRank · unranked

76 citations

Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila +18 more

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Frontiers in Oncology(2022)10.3389/fonc.2022.802579

N/A

0DataRank · unranked

16 citations

Özge Gümüşay, Razelle Kurzrock, L. J. van ‘t Veer, Hope S. Rugo, Mark Jesus M. Magbanua

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.504

N/A

0DataRank · unranked

15 citations

Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, A. Jo Chien, Christina Yau +7 more

Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.591

N/A

0DataRank · unranked

6 citations

Rebecca Shatsky, Christina Yau, Denise M. Wolf, Rita Nanda, L. J. van ‘t Veer +4 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510

N/A

0DataRank · unranked

1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.592

N/A

0DataRank · unranked

1 citations

Paige Warner, Robert Hiatt, Scarlett Lin Gomez, L. J. van ‘t Veer, Allison Stover Fiscalini +11 more

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF V600E colorectal tumors

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.10.20.512885

N/A

0DataRank · unranked

0 citations

Chloé E. Atreya, Changjun Wang, Bo Pan, Courtney A. Dreyer, Diede Brunen +20 more

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

Molecular Cancer(2023)10.1186/s12943-022-01710-w

N/A

0DataRank · unranked

270 citations

Hani Goodarzi, Josef Srovnal, Marián Hajdúch, L. J. van ‘t Veer, Mark Jesus M. Magbanua +1 more

L. J. van ‘t Veer

Indexed papers

Top data-sharing exemplar

Papers